This randomized , double-blind , placebo-controlled parallel-group study assessed the effects of sodium glucose cotransporter 2 inhibition by dapagliflozin on insulin sensitivity and secretion in subjects with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue ) .